Top Markets
Coin of the day
Yumanity Therapeutics, Inc. Yumanity Therapeutics, Inc.

Yumanity Therapeutics, Inc.

YMTX
Rank in Stocks #28846
Yumanity Therapeutics Inc. operates as a clinical-stage biopharmaceutical... Yumanity Therapeutics Inc. operates as a clinical-stage biopharmaceutical company. Its primary focus lies in the investigation and development of therapeutic solutions for neurodegenerative conditions, particularly those driven by protein misfolding. The firm aims to discover disease-modifying treatments for a range of neurodegenerative disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis (ALS), and frontotemporal lobar degeneration. Central to its pipeline is YTX-7739, an innovative small molecule presently in Phase I clinical trials for Parkinson's disease and associated α-synuclein disorders. Additionally, YTX-9184 is undergoing preclinical studies with the goal of treating diverse neurological conditions. The company maintains a license and research collaboration agreement with Merck Sharp & Dohme Corp. Founded in 2014, Yumanity Therapeutics Inc. is headquartered in Boston, Massachusetts.
Share Price
$1.89
Last synced: 2022-12-16
Market Cap
$24.38M
Change (1 day)
8.62%
Change (1 year)
0.00%
Country
US
Trade Yumanity Therapeutics, Inc. (YMTX)

Category

Earnings for Yumanity Therapeutics, Inc. (YMTX)
Earnings in 2026 TTM: 0
According to Yumanity Therapeutics, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Yumanity Therapeutics, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$1.61B -
AU
- -
CH